Matritech (NASDAQ - NMPS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Matritech (NASDAQ - NMPS)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: R Sandvig who wrote (708)	11/19/1998 9:31:00 PM
From: eugenic1	Read Replies (1) of 849

With only 5.6 million in cash as of 9-30-1998, the announcement today should give a bit of relief to the cash concerns. The three big labs utilizing the nmp22 should provide a boost. The cervical, breast, colon, and prostate cancer product R&D can move forward at full bore. Insiders purchased a few shares back in Sept, and the light at the end of the tunnel is visible again. biz.yahoo.com The sales in Japan should pick up going forward, as the nmp22 is continuing to gain acceptance as the standard. best returns

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next